JP2017523974A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523974A5
JP2017523974A5 JP2017505180A JP2017505180A JP2017523974A5 JP 2017523974 A5 JP2017523974 A5 JP 2017523974A5 JP 2017505180 A JP2017505180 A JP 2017505180A JP 2017505180 A JP2017505180 A JP 2017505180A JP 2017523974 A5 JP2017523974 A5 JP 2017523974A5
Authority
JP
Japan
Prior art keywords
composition
methotrexate
months
administered
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017505180A
Other languages
English (en)
Japanese (ja)
Other versions
JP7097181B2 (ja
JPWO2016019165A5 (enExample
JP2017523974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/042951 external-priority patent/WO2016019165A1/en
Publication of JP2017523974A publication Critical patent/JP2017523974A/ja
Publication of JP2017523974A5 publication Critical patent/JP2017523974A5/ja
Publication of JPWO2016019165A5 publication Critical patent/JPWO2016019165A5/ja
Application granted granted Critical
Publication of JP7097181B2 publication Critical patent/JP7097181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017505180A 2014-07-30 2015-07-30 増殖性硝子体網膜症用メトトレキサート Active JP7097181B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462030778P 2014-07-30 2014-07-30
US62/030,778 2014-07-30
PCT/US2015/042951 WO2016019165A1 (en) 2014-07-30 2015-07-30 Methotrexate for proliferative vitreoretinopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020202357A Division JP2021059554A (ja) 2014-07-30 2020-12-07 増殖性硝子体網膜症用メトトレキサート

Publications (4)

Publication Number Publication Date
JP2017523974A JP2017523974A (ja) 2017-08-24
JP2017523974A5 true JP2017523974A5 (enExample) 2018-09-06
JPWO2016019165A5 JPWO2016019165A5 (enExample) 2022-04-27
JP7097181B2 JP7097181B2 (ja) 2022-07-07

Family

ID=55218325

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017505180A Active JP7097181B2 (ja) 2014-07-30 2015-07-30 増殖性硝子体網膜症用メトトレキサート
JP2020202357A Pending JP2021059554A (ja) 2014-07-30 2020-12-07 増殖性硝子体網膜症用メトトレキサート
JP2023114963A Pending JP2023145527A (ja) 2014-07-30 2023-07-13 増殖性硝子体網膜症用メトトレキサート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020202357A Pending JP2021059554A (ja) 2014-07-30 2020-12-07 増殖性硝子体網膜症用メトトレキサート
JP2023114963A Pending JP2023145527A (ja) 2014-07-30 2023-07-13 増殖性硝子体網膜症用メトトレキサート

Country Status (6)

Country Link
US (4) US10098884B2 (enExample)
EP (3) EP3174540B9 (enExample)
JP (3) JP7097181B2 (enExample)
CA (2) CA3200870A1 (enExample)
ES (2) ES2835499T3 (enExample)
WO (1) WO2016019165A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2835499T3 (es) * 2014-07-30 2021-06-22 Massachusetts Eye & Ear Infirmary Metotrexato para la vitreorretinopatía proliferativa
WO2018027044A1 (en) * 2016-08-05 2018-02-08 Schepens Eye Research Institute Idelalisib for treating proliferative vitreoretinopathy and abnormal intraocular neovascularization
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CN114423432A (zh) * 2019-09-13 2022-04-29 奥尔德拉医疗公司 甲氨蝶呤的眼用制剂
CN115804665A (zh) * 2022-12-13 2023-03-17 南昌大学附属眼科医院 一种tpvr动物模型的建立方法
WO2024129979A1 (en) * 2022-12-14 2024-06-20 Aldeyra Therapeutics, Inc. Methotrexate treatment methods
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032734A1 (en) 2000-07-26 2002-03-14 Rhoads Geoffrey B. Collateral data combined with user characteristics to select web site
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
WO2005095464A1 (ja) * 2004-04-02 2005-10-13 Denki Kagaku Kogyo Kabushiki Kaisha ヒアルロン酸－メトトレキサート結合体
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
ATE439123T1 (de) 2004-07-02 2009-08-15 Novagali Pharma Sa Verwendung von emulsionen zur intra- und periocularen injection
MX344532B (es) * 2004-10-01 2016-12-19 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
US20110200662A1 (en) 2008-10-22 2011-08-18 Arnold Glazier Method For The Treatment Of Proliferative Disorders Of The Eye
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US20140105956A1 (en) * 2012-10-11 2014-04-17 Rupak BANERJEE Biodegradable polymer based microimplant for ocular drug delivery
EP4566672A3 (en) * 2012-11-08 2025-08-13 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
ES2835499T3 (es) * 2014-07-30 2021-06-22 Massachusetts Eye & Ear Infirmary Metotrexato para la vitreorretinopatía proliferativa

Similar Documents

Publication Publication Date Title
JP2017523974A5 (enExample)
RU2760682C2 (ru) Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции
JP2016535777A5 (enExample)
HRP20160330T1 (hr) Inhibitori janus kinaze za liječenje suhog oka i drugih očnih bolesti
JP2016540785A5 (enExample)
JP2015528454A5 (enExample)
JP2016027060A5 (enExample)
JP2011173928A5 (enExample)
JP2019517542A5 (enExample)
JP2015526467A5 (enExample)
PH12016501357A1 (en) Pharmaceutical preparation containing pyridylamino acetic acid compound
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
JP2021152060A (ja) アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
US20200147081A1 (en) Use of Kinase Inhibitors to Manage Tuberculosis and Other Infectious Diseases
RU2017112930A (ru) Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
JP2017527600A5 (enExample)
Huang et al. Physicochemical properties and in vivo assessment of timolol-loaded poly (D, L-lactide-co-glycolide) films for long-term intraocular pressure lowering effects
JP2019532095A5 (enExample)
JP2007517885A5 (enExample)
JP2019533672A5 (enExample)
CN102596194A (zh) 组合药物
WO2014204357A3 (ru) Лекарственное средство для лечения кератоконуса
Musmade et al. Fusidic acid–Topical antimicrobial in the management of Staphylococcus aureus
AU2021252229A1 (en) Endoxifen for the treatment of bipolar I disorder
JP2018529747A5 (enExample)